Interleukin-6 in synovial fluid and HLA-DR expression in synovium from patients with temporomandibular disorders.

Interleukin-6-dependent mouse hybridoma cell line KD83 was used to test the biologic activity of interleukin-6 in synovial fluid from 37 patients with temporomandibular disorders. The results showed that the interleukin-6 level was greater than 100 U/mL in 13 of 18 patients with degenerative joint disease and in five of 12 patients with temporomandibular disc displacement. However, the interleukin-6 level was less than 100 U/mL (range, 20 to 75 U/mL) in all patients with masticatory muscle disorder. It has been found that degenerative joint disease tends to have acute and chronic stages, and interleukin-6 activity was probably related to the acute stage in the patients. Histologic studies of the synovium from seven patients with degenerative joint disease showed a variable degree of hyperplasia of the synovial lining cells and chronic inflammation in five of eight specimens. Immunostaining studies clearly showed the presence of significantly more HLA-DR-expressing cells (human leukocyte antigen-D-related) in synovium. Although it is unlikely that immune responses play an important primary role in initiating synovial inflammation and cartilage destruction, immune reactions may be one important factor in the maintenance and severity of some patients with temporomandibular disorders.

[1]  N. Segami,et al.  Correlation between pain and synovitis in patients with internal derangement of the temporomandibular joint. , 1991, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[2]  Jasin He,et al.  Antigen presentation in the rheumatoid joint. , 1991 .

[3]  T. Hirano,et al.  IL-6 is produced by osteoblasts and induces bone resorption. , 1990, Journal of immunology.

[4]  N. Bazan,et al.  Identification of prostaglandin E2 and leukotriene B4 in the synovial fluid of painful, dysfunctional temporomandibular joints. , 1990, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[5]  J. Hamilton,et al.  Effects of tumor necrosis factor α and β on resorption of human articular cartilage and production of plasminogen activator by human articular chondrocytes , 1990 .

[6]  T. Espevik,et al.  Interleukin-6 in synovial fluid from patients with arthritis. , 1989, Clinical immunology and immunopathology.

[7]  S. Krane,et al.  Interleukin 1 suppresses expression of cartilage-specific types II and IX collagens and increases types I and III collagens in human chondrocytes. , 1988, The Journal of clinical investigation.

[8]  G. Nuki,et al.  Tumour necrosis factor in synovial exudates. , 1988, Annals of the rheumatic diseases.

[9]  S. Lindblad,et al.  Arthroscopic and immunohistologic characterization of knee joint synovitis in osteoarthritis. , 1987, Arthritis and rheumatism.

[10]  M. Feldmann,et al.  HLA class II induction in human islet cells by interferon-γ plus tumour necrosis factor or lymphotoxin , 1987, Nature.

[11]  S. Goodman,et al.  Cytokines and the chronic inflammation of rheumatic disease. II. The presence of interleukin-2 in synovial fluids. , 1984, Clinical and experimental immunology.

[12]  M. Xu-chen,et al.  Radiographic, pathological and operative observations of cases with TMJ disturbance syndrome. , 1983 .

[13]  D. Goldenberg,et al.  Inflammatory synovitis in degenerative joint disease. , 1982, The Journal of rheumatology.